Breast Cancer Research and Treatment

, Volume 122, Issue 3, pp 795–801

The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literatures

  • Liheng Zhou
  • Yiwei Jiang
  • Tingting Yan
  • Genhong Di
  • Zhenzhou Shen
  • Zhimin Shao
  • Jinsong Lu
Clinical trial

DOI: 10.1007/s10549-010-0999-4

Cite this article as:
Zhou, L., Jiang, Y., Yan, T. et al. Breast Cancer Res Treat (2010) 122: 795. doi:10.1007/s10549-010-0999-4

Abstract

CD44+/CD24−/low tumor cells or aldehyde dehydrogenase 1 (ALDH1) positive tumor cells are considered cancer stem cells (CSCs) that possess the properties of self-renewal and tumorigenicity. However, their clinical value and significance in breast cancer remain controversial. A meta-analysis based on published studies was performed with the aim of obtaining an accurate evaluation of the association between the presence of CSCs in clinical samples and clinical outcome. A total of 12 eligible studies with 898 cases and 1,853 controls were included. CSC positive breast cancers, in particular those positive for ALDH1, were significantly associated with high histological grade, estrogen receptor (ER) negativity, progesterone receptor (PR) negativity, and human epidermal growth factor receptor type 2 (HER2) positivity. However, the presence of cancer stem cells was not associated with tumor size or nodal status. ALDH1 positive (RR = 2.83, 95% CI: 2.16–3.67, P < 0.001) and CD44+/CD24−/low tumor cells (RR = 2.32, 95% CI: 1.51–3.60, P < 0.001) were significantly associated with poor overall survival (OS). The stem cell markers are prognostic factors in breast cancer. Larger clinical studies are required to further evaluate the role of these markers in clinical practice.

Keywords

Breast cancer Breast cancer stem cells ALDH1 CD44+/CD24−/low 

Supplementary material

10549_2010_999_MOESM1_ESM.doc (28 kb)
Supplementary material 1 (DOC 27 kb)

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Liheng Zhou
    • 1
    • 2
  • Yiwei Jiang
    • 1
    • 2
  • Tingting Yan
    • 1
    • 2
  • Genhong Di
    • 1
    • 2
  • Zhenzhou Shen
    • 1
    • 2
  • Zhimin Shao
    • 1
    • 2
  • Jinsong Lu
    • 1
    • 2
  1. 1.Department of Breast Surgery, Shanghai Cancer Hospital/Cancer InstituteFudan UniversityShanghaiChina
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina

Personalised recommendations